Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psychotropic medication use in Canada.

Cynthia A Beck1, Jeanne V A Williams, Jian Li Wang

  • 1Department of Psychiatry, University of Calgary, Alberta. cindy.beck@calgaryhealthregion.ca

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|November 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The many faces of the multiple sclerosis population in Canada.

Multiple sclerosis and related disorders·2026
Same author

Resident-focused trauma-informed medical education policies: an environmental scan of Canadian medical schools and partner organizations.

Canadian medical education journal·2026
Same author

Privilege breeds privilege: a descriptive analysis of medical students' ethno-racial identity and capital to inform diversity, equity and inclusion in Canadian medical education.

BMC medical education·2026
Same author

Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Risk of all-cause and cause-specific mortality, and suicide attempt in people with anxiety and stress-related disorders: a systematic review, meta-analysis and meta-regression analysis of 165 studies.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Sex-based differences in penicillin allergy labeling among adults in a Canadian ambulatory urgent medicine clinic: a cross-sectional study.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026

Psychotropic medication use in Canada was 7.2% overall, significantly higher in individuals with diagnosed mental health disorders. Antidepressant use was common for major depressive episodes, while sedative-hypnotic use increased with age.

Area of Science:

  • Psychiatry and Mental Health Research
  • Public Health and Epidemiology
  • Pharmacology

Background:

  • Psychotropic medication use serves as an indicator for appropriate mental disorder treatment.
  • The Canadian Community Health Survey (CCHS 1.2) provides national data on psychotropic medication use linked to diagnostic groups.
  • This study utilizes the Composite International Diagnostic Interview (CIDI) for diagnostic assessments.

Purpose of the Study:

  • To characterize national psychotropic medication use in Canada.
  • To analyze medication use across different diagnostic groups and demographic subgroups.
  • To provide a benchmark for international comparisons of psychotropic drug utilization.

Main Methods:

  • Assessed prevalence of five classes of psychotropic medications: antidepressants, sedative-hypnotics, mood stabilizers, psychostimulants, and antipsychotics.

Related Experiment Videos

  • Utilized data from the Canadian Community Health Survey (CCHS 1.2) with full Composite International Diagnostic Interview (CIDI) diagnostic assessments.
  • Employed sampling weights and bootstrap methods for robust statistical analysis.

    • Main Results:

    • Overall psychotropic medication use was 7.2%, rising to 19.3% in individuals with any lifetime CIDI-diagnosed disorder.
    • Selective serotonin reuptake inhibitors (SSRIs) were the most common antidepressants for past-year major depressive episodes.
    • Sedative-hypnotic use increased with age, reaching 11.1% in those over 75 years.

    Conclusions:

    • Canadian antidepressant use may be higher and antipsychotic use lower compared to recent European and American reports.
    • Antidepressant use in adolescents (15-19 years) may decline due to limited evidence of efficacy.
    • Increased sedative-hypnotic use in seniors is a concern due to associated adverse effect risks.